Combination pills for EGFR-mutant lung cancer after pill failure
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two oral targeted pills for people with a specific EGFR-mutated lung cancer that has progressed after prior targeted therapy. It explores whether adding a second drug (Anlotinib) can overcome resistance.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-squamous non-small cell lung cancer that is advanced or has spread.
- Your tumor has an EGFR mutation (like 19del, L858R, or T790M).
- You have tried an EGFR pill (like Osimertinib) and it stopped working, or you couldn't tolerate it.
- You are not currently able or willing to have chemotherapy.
- You are in fairly good health (able to do light activities, up and about).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug sunvozertinib before and after surgery for non-small cell lung cancer that has a specific EGFR mutation (exon 20 insertion). It aims to see if the drug can help shrink tumors and improve outcomes for patients whose cancer is at stage II, IIIA, or IIIB.
This trial tests a combination of two targeted pills (sunvozertinib and anlotinib) as a first treatment for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if this combination works better than current standard treatments.
This trial tests a new combination of two oral targeted drugs for people with advanced non-small cell lung cancer that has an EGFR mutation. It may help if you have already been treated with a third-generation EGFR pill or if you are starting treatment for the first time.
This trial tests a new pill (sunvozertinib) combined with chemotherapy for people with a specific EGFR mutation type of lung cancer whose previous targeted pill stopped working. It aims to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two oral drugs (sunvozertinib and anlotinib) as a first treatment for advanced lung cancer with certain EGFR mutations plus other gene changes. It aims to see if this combination works better than standard treatments.
This study tests a new targeted therapy, sunvozertinib, for people with a specific type of advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to previous treatments. It may be an option if you have already tried chemotherapy and an EGFR-targeting drug.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.